Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

A 28-year-old male started a hair loss treatment with 2.5mg oral minoxidil daily, 1mg finasteride every other day, and a 1.5mm dermaroller once a week. After two months, he believes he sees some progress.

RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.

The user experienced significant hair regrowth using 5% topical minoxidil and 1mg finasteride daily, despite multiple shedding phases, and emphasizes the importance of starting treatment early and maintaining consistency. They advise against obsessing over online forums during shedding periods and recommend checking for scalp conditions like seborrheic dermatitis and ensuring proper nutrition.

A user is experiencing hair loss in the center of their hairline and has been using topical finasteride for seven months with minimal progress. They are considering switching treatments due to concerns about losing ground and potential side effects of other options.

A user shared their positive experience with a hair transplant journey over 10 years, involving 3000+ grafts and regular use of minoxidil and finasteride. Other users commented on the hairstyle and suggested alternative treatments like SMP or hairpieces.

OP used 0.4 mg Dutasteride and 2 mg Minoxidil for 7 months, seeing significant hair density improvement without a noticeable shedding phase. OP takes a combined oral pill from Musely and is in their early forties.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

A 22-year-old male is on day 77 of using 1 mg finasteride for hair loss. He reports decreased oiliness and shedding but is unsure about overall progress.

The user noticed hair thinning since age 15, initially attributed to a Vitamin D deficiency. They are currently using Rogaine and considering Propecia but are hesitant about a scalp biopsy; they seek financially practical treatments for male-pattern baldness.

The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.

Pyrilutamide 0.9% (kx-826) is available for shipping to Europe from Amazon US and Koshinemall. Shipping costs and availability vary between the two shops.

User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

Switching from liquid to foam minoxidil led to hair loss for OP, possibly due to a second shedding cycle. OP experienced allergic reactions to propylene glycol in the liquid form, causing dandruff and itchiness, which improved after switching to foam.

The user reported hair thickening and new growth after using minoxidil and microneedling for over three months. They are considering finasteride but have not started it yet.

A user shared their progress using liquid minoxidil for hair regrowth and plans to switch to foam minoxidil due to flaking. They asked if the foam version would maintain their results and mentioned considering adding finasteride and a derma pen soon.

A 25-year-old shared progress in hair regrowth after 7 months using dutasteride, minoxidil, and microneedling, noting some baby hair growth on the temples. The user plans to continue this treatment, having found it effective despite some initial shedding and challenges with styling due to topical minoxidil.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

A 19-year-old is using topical minoxidil 7% and finasteride 0.1% foam, along with a laser cap, to combat hair loss. They report progress despite initial shedding and are considering switching to oral finasteride in the future for convenience.

The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.

The user shared progress pictures after 5 months of using 1mg finasteride, weekly 1.5mm microneedling, and daily 2mg copper peptide injections. They discussed their hair loss treatment and results.

A user's progress with hair loss treatments over 5 months, using topical finasteride (0.3%) and minoxidil (6%), as well as weekly microneedling sessions; other users have asked questions about the results and offered compliments.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

A 21-year-old woman diagnosed with male pattern baldness (MPB) who is considering treatments such as spironolactone, minoxidil and finasteride to address her hair loss. The user also discusses potential solutions for concealing the appearance of her thinning hair, such as wigs or haircuts.